Area of research
Hematology · Molecular Biology
Research interest
I am Professor of Medicine, Chief of the Myeloma Division, and Co-Leader of the Translational and Clinical Oncology (TCO) Program at NCI-designated Sylvester Comprehensive Cancer Center (Sylvester). In my Co-Leader role, I work closely with Dr. Jaime Merchan to oversee the clinical and research operations for TCO as well as the development of the research program. Dr. Merchan and I complement each other's talents and strengths and serve as key conduits to move science from the lab into the clinic, and vice versa. As a Cancer Center Support Grant member, I participate in research activities as an independent investigator, as a leader of research governance committees, and I serve on multi-disciplinary research teams.
Tocilizumab prophylaxis for patients with multiple myeloma treated with bispecific antibodies
Biallelic antigen escape is a mechanism of resistance to anti-CD38 antibodies in multiple myeloma
Temporal genomic dynamics shape clinical trajectory in multiple myeloma
Bruton’s tyrosine kinase inhibition re-sensitizes multidrug-resistant DLBCL tumors driven by BCL10 gain-of-function mutants to venetoclax
A High-Fiber, Plant-Based Diet in Myeloma Precursor Disorders: Results from the NUTRIVENTION Clinical Trial and Preclinical Vk*MYC Model
CD38-Targeted<sup>89</sup>Zr-DFO-Daratumumab PET of Myeloma: Immuno-PET Impacting Clinical Care
A proinflammatory response and polarized differentiation of stromal elements characterizes the murine myeloma bone marrow niche
New Definition of Light Chain Monoclonal Gammopathy of Undetermined Significance
Genomics Define Malignant Transformation in Myeloma Precursor Conditions
Timing Genomic Antigen Loss in Multiple Myeloma Treated with T Cell–Redirecting Immunotherapies
Mutagenic Impact and Evolutionary Influence of Chemoradiotherapy in Hematologic Malignancies
Knowledge-informed multimodal cfDNA analysis improves sensitivity and generalization in cancer detection
Epigenetic Plasticity Drives Carcinogenesis and Multi-Therapy Resistance in Multiple Myeloma
Genomic Classification and Individualized Prognosis in Multiple Myeloma
Impact of soluble BCMA and non–T-cell factors on refractoriness to BCMA-targeting T-cell engagers in multiple myeloma
Genomic and immune determinants of resistance to daratumumab-based therapy in relapsed refractory multiple myeloma
Efficacy and safety of daratumumab in intermediate/high-risk smoldering multiple myeloma: final analysis of CENTAURUS
Genomic Profiling to Contextualize the Results of Intervention for Smoldering Multiple Myeloma
The biological and clinical impact of deletions before and after large chromosomal gains in multiple myeloma
Development of a Multivariable Model to Predict the Need for Bone Marrow Sampling in Persons With Monoclonal Gammopathy of Undetermined Significance
The genomic landscape of Vk*MYC myeloma highlights shared pathways of transformation between mice and humans
Single-cell analysis of the multiple myeloma microenvironment after γ-secretase inhibition and CAR T-cell therapy
Tocilizumab Prophylaxis for Patients with Relapsed or Refractory Multiple Myeloma Treated with Teclistamab, Elranatamab or Talquetamab
Genomic Determinants of Resistance to Anti-BCMA Chimeric Antigen Receptor T-Cell (CART) Therapies in Patients with Relapsed/Refractory Multiple Myeloma
Monoclonal gammopathy of undetermined significance and the risk of thrombotic events: Results from iStopMM, a prospective population‐based screening study
Evaluating serum free light chain ratio as a biomarker in multiple myeloma
First-in-Human Phase 1 Study of SAR442257 in Patients with Relapsed/Refractory Multiple Myeloma and Non-Hodgkin Lymphoma
CD38 biallelic loss is a recurrent mechanism of resistance to anti-CD38 antibodies in multiple myeloma
Excess Risk of Monoclonal Gammopathy of Undetermined Significance (MGUS) in a Screened Cohort of Patients with Gaucher Disease (GD)
Temporal Genomic Dynamics Shape Clinical Trajectory in Multiple Myeloma